WntResearch announced that a member of the company's Board of Directors, Professor Bengt Glimelius, has been appointed to lead the issuing of guidelines for colorectal cancer care in Sweden, by The National Board of Health. Since this assignment is incompatible with board positions at pharmaceutical companies, Professor Glimelius has announced the company that he will have to leave his position at the company. He will however continue as an independent medical consultant to the company. Bengt Glimelius will leave his position as board member in August 2016.